A computationally designed immunogen elicits potent anti-V3 neutralizing antibodies

被引：0
|
作者：
Carrico, C. T. [1 ]
Lagerquist, E. [2 ]
Boni, E. [3 ]
Ban, Y. A. [1 ]
Bretz, C. [3 ]
Ellingson, K. [2 ]
Kalyuzhniy, O. [1 ]
Montefiori, D. [4 ]
Strong, R. [3 ]
Stamatatos, L. [2 ]
Schief, W. [1 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Seattle Biomed Res Inst, Seattle, WA 98109 USA
[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[4] Duke Univ, Durham, NC USA
来源：
RETROVIROLOGY | 2009年 / 6卷
关键词：
Surface Plasmon Resonance; Scaffold Protein; Computational Design; Modeling Platform; Structural Search;
D O I：
10.1186/1742-4690-6-S3-P88
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Identification of a clade A HIV envelope immunogen from Protocol G that elicits neutralizing antibodies to tier 2 viruses
    S Hoffenberg
    S Kosakovsky Pond
    A Carpov
    D Wagner
    A Wilson
    R Powell
    R Lindsay
    H Arendt
    J DeStefano
    P Poignard
    M Simek
    S Fling
    S Phogat
    C Labranche
    D Montefiori
    D Burton
    C Parks
    C King
    W Koff
    M Caulfield
    Retrovirology, 9
  • [22] Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies
    Almond, David
    Krachmarov, Chavdar
    Swetnam, James
    Zolla-Pazner, Susan
    Cardozo, Timothy
    ADVANCES IN VIROLOGY, 2012, 2012
  • [23] Identification of a clade A HIV envelope immunogen from Protocol G that elicits neutralizing antibodies to tier 2 viruses
    Hoffenberg, S.
    Pond, S. Kosakovsky
    Carpov, A.
    Wagner, D.
    Wilson, A.
    Powell, R.
    Lindsay, R.
    Arendt, H.
    DeStefano, J.
    Poignard, P.
    Simek, M.
    Fling, S.
    Phogat, S.
    Labranche, C.
    Montefiori, D.
    Burton, D.
    Parks, C.
    King, C.
    Koff, W.
    Caulfield, M.
    RETROVIROLOGY, 2012, 9
  • [24] A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin
    Sautto, Giuseppe A.
    Kirchenbaum, Greg A.
    Abreu, Rodrigo B.
    Ecker, Jeffrey W.
    Pierce, Spencer R.
    Kleanthous, Harry
    Ross, Ted M.
    JOURNAL OF IMMUNOLOGY, 2020, 204 (02): : 375 - 385
  • [25] ANTI-V3 ANTIBODIES FAIL TO INHIBIT CELL-TO-CELL TRANSMISSION OF HIV-1
    DEMAREST, JF
    PANTALEO, G
    ZOLLAPAZNER, S
    BANSAL, G
    KOENIG, S
    FAUCI, AS
    JOURNAL OF IMMUNOLOGY, 1993, 150 (08): : A317 - A317
  • [26] P20-09. Worldwide epitope prevalence of crystallographically resolved anti-V3 antibodies
    J Swetnam
    S Zolla-Pazner
    TJ Cardozo
    Retrovirology, 6
  • [27] Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate
    Shibata, Junji
    Yoshimura, Kazuhisa
    Honda, Akiko
    Koito, Atsushi
    Murakami, Toshio
    Matsushita, Shuzo
    JOURNAL OF VIROLOGY, 2007, 81 (08) : 3757 - 3768
  • [28] ANTI-V3 ANTIBODY REACTIVITY CORRELATES WITH CLINICAL STAGE OF HIV-1 INFECTION AND WITH SERUM NEUTRALIZING ACTIVITY
    FENOUILLET, E
    BLANES, N
    BENJOUAD, A
    GLUCKMAN, JC
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1995, 99 (03): : 419 - 424
  • [29] A rationally designed synthetic peptide mimic of a discontinuous viral antigenic site elicits neutralizing antibodies
    Borràs, E
    Giralt, E
    Andreu, D
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1999, 121 (50) : 11932 - 11933
  • [30] Worldwide Distribution of HIV Type 1 Epitopes Recognized by Human Anti-V3 Monoclonal Antibodies
    Cardozo, Timothy
    Swetnam, James
    Pinter, Abraham
    Krachmarov, Chavdar
    Nadas, Arthur
    Almond, David
    Zolla-Pazner, Susan
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2009, 25 (04) : 441 - 450
12345